受让方未完全履约 艾德生物发起仲裁追讨千万元技术转让款

Core Viewpoint - The company Aide Biology has initiated arbitration against Aivek for unpaid technology transfer fees amounting to 13.95 million yuan, following a previous agreement for a cancer early detection product [1][3][5]. Group 1: Arbitration Details - Aide Biology received an arbitration notice regarding a dispute over a technology transfer and licensing agreement with Aivek, with the claimed amount being 13.95 million yuan [1]. - The arbitration case involves a technology transfer fee that was previously recognized as a loss in the company's financial statements, indicating that it does not expect significant adverse effects on profits for the current and future years [1][5]. - The arbitration seeks to recover the unpaid technology transfer fee and associated penalties, totaling 13.35 million yuan in principal and 600,000 yuan in legal fees [5]. Group 2: Background of the Agreement - The technology transfer agreement was signed in June 2022, involving a cancer early detection product, the human SDC2 gene methylation detection kit, with a total transfer fee of 100 million yuan [3][4]. - Aide Biology initially received 50 million yuan as the first payment, with subsequent payments scheduled over four years, but Aivek has failed to make the second payment due in August 2024 [4][6]. - The product in question is significant as it was the first approved cancer early detection product by Aide Biology, enhancing its competitive position in the market [6][7]. Group 3: Strategic Rationale for the Transfer - Aide Biology's decision to transfer the asset was based on the differing commercialization models of cancer early detection products compared to its existing drug companion diagnostics, which made synergy with its sales team challenging [6][7]. - The company viewed the sale as an attempt to explore new commercial promotion models for cancer early detection products, acknowledging the need for substantial resources and the uncertainty of future returns [7].